×
About 1,066 results

ALLMedicine™ Agammaglobulinemia Center

Research & Reviews  475 results

The Clinical Course of COVID-19 Pneumonia in a 19-Year-Old Man on Intravenous Immunoglo...
https://doi.org/10.12659/AJCR.929447
The American Journal of Case Reports; Almontasheri A, Al-Husayni F et. al.

Feb 22nd, 2021 - BACKGROUND Since the emergence of coronavirus disease 2019 (COVID-19), patients with the illness have presented with considerable variation in severity. Some infected individuals present mild or no symptoms, while others present severe illness wit...

Agammaglobulinemia with normal B-cell numbers in a patient lacking Bob1.
https://doi.org/10.1016/j.jaci.2021.01.027
The Journal of Allergy and Clinical Immunology; Kury P, Staniek J et. al.

Feb 11th, 2021 - Bob1 deficiency reduces B-cell responsiveness, impairs plasmablast formation and immunoglobulin secretion. Bob1 deficiency presents with increased susceptibility to respiratory infections and agammaglobulinemia despite normal B-cell numbers.

Home and office blood pressure: time to look at the individual patient.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4321335
Hypertension Research : Official Journal of the Japanese ... de Leeuw PW

Feb 2nd, 2021 - Most genetic defects that arrest B-cell development in the bone marrow present early in life with agammaglobulinemia, whereas incomplete antibody deficiency is usually associated with circulating B cells. We report 3 related individuals with a nov...

Novel mutations in hyper-IgM syndrome type 2 and X-linked agammaglobulinemia detected i...
https://doi.org/10.1002/mgg3.1552
Molecular Genetics & Genomic Medicine REFERENCES; Chen X, Liu F et. al.

Dec 30th, 2020 - Ambiguous or atypical phenotypes can make a definite diagnosis of primary immunodeficiency diseases based on biochemical indices alone challenging. Further, mortality in early life because of infections in patients with these conditions supports t...

Ecthyma gangrenosum due to Pseudomonas aeruginosa sepsis as initial manifestation of X-...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7704585
BMC Pediatrics; Huang H, Bai K et. al.

Dec 2nd, 2020 - X-linked agammaglobulinemia (XLA, OMIM#300,300), caused by mutations in the Bruton tyrosine kinase (BTK) gene, is a rare monogenic inheritable immunodeficiency disorder. Ecthyma gangrenosum is a cutaneous lesion caused by Pseudomonas aeruginosa th...

see more →

Drugs  39 results see all →

Clinicaltrials.gov  537 results

The Clinical Course of COVID-19 Pneumonia in a 19-Year-Old Man on Intravenous Immunoglo...
https://doi.org/10.12659/AJCR.929447
The American Journal of Case Reports; Almontasheri A, Al-Husayni F et. al.

Feb 22nd, 2021 - BACKGROUND Since the emergence of coronavirus disease 2019 (COVID-19), patients with the illness have presented with considerable variation in severity. Some infected individuals present mild or no symptoms, while others present severe illness wit...

Agammaglobulinemia with normal B-cell numbers in a patient lacking Bob1.
https://doi.org/10.1016/j.jaci.2021.01.027
The Journal of Allergy and Clinical Immunology; Kury P, Staniek J et. al.

Feb 11th, 2021 - Bob1 deficiency reduces B-cell responsiveness, impairs plasmablast formation and immunoglobulin secretion. Bob1 deficiency presents with increased susceptibility to respiratory infections and agammaglobulinemia despite normal B-cell numbers.

Home and office blood pressure: time to look at the individual patient.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4321335
Hypertension Research : Official Journal of the Japanese ... de Leeuw PW

Feb 2nd, 2021 - Most genetic defects that arrest B-cell development in the bone marrow present early in life with agammaglobulinemia, whereas incomplete antibody deficiency is usually associated with circulating B cells. We report 3 related individuals with a nov...

Novel mutations in hyper-IgM syndrome type 2 and X-linked agammaglobulinemia detected i...
https://doi.org/10.1002/mgg3.1552
Molecular Genetics & Genomic Medicine REFERENCES; Chen X, Liu F et. al.

Dec 30th, 2020 - Ambiguous or atypical phenotypes can make a definite diagnosis of primary immunodeficiency diseases based on biochemical indices alone challenging. Further, mortality in early life because of infections in patients with these conditions supports t...

Xembify - immune globulin subcutaneous, human-klhw solution-GRIFOLS USA, LLC
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8c174b11-a061-412e-a3b2-7bf7e1adaace

Dec 28th, 2020 - XEMBIFY® (immune globulin subcutaneous, human – klhw) is a 20% immune globulin solution for subcutaneous injection indicated for treatment of primary humoral immunodeficiency (PI) in patients 2 years of age and older. This includes, but is not lim...

see more →

News  11 results

Dyspnea and Night Sweats in a 46-Year-Old Man
https://reference.medscape.com/viewarticle/732961_3

Jan 14th, 2020 - Which of the following is the most likely diagnosis? Your Peers Chose: Bruton agammaglobulinemia 0% Thymoma 0% Pheochromocytoma 0% Teratoma 0% Discussion The patient in this case was eventually diagnosed with thymoma. Symptoms from a thymoma or th...

FDA OKs Immunoglobulin Xembify for Primary Immunodeficiencies
https://www.medscape.com/viewarticle/915280

Jul 4th, 2019 - The US Food and Drug Administration (FDA) has approved a 20% immune globulin solution for subcutaneous injection (Xembify, Grifols) to treat primary immunodeficiencies in patients as young as 2 years old, according to a company statement. The appr...

FDA approves IVIG product for PI and chronic ITP
https://www.mdedge.com/hematology-oncology/article/186860/anemia/fda-approves-ivig-product-pi-and-chronic-itp
HT Staff

Feb 9th, 2017 - Vials of product Photo by Bill Branson The US Food and Drug Administration (FDA) has approved an intravenous immunoglobulin (IVIG) product (Gammaplex® 10%) for the treatment of primary immunodeficiency (PI) and chronic immune thrombocytopenia (ITP.

FDA approves IVIG product for kids
https://www.mdedge.com/hematology-oncology/article/187717/pediatrics/fda-approves-ivig-product-kids
HT Staff

Aug 7th, 2015 - Vials of drug Photo by Bill Branson The US Food and Drug Administration (FDA) has approved an intravenous human immune globulin (IVIG) product (Gammaplex) for pediatric patients age 2 years and older who have primary humoral immunodeficiencies. Th.

Octagam Withdrawn From Market Over Unresolved Blood Clots, Embolisms
https://www.medscape.com/viewarticle/729411

Sep 23rd, 2010 - September 24, 2010 — Octapharma USA is voluntarily withdrawing all lots of immune globulin G (IgG) intravenous (human) 5% liquid preparation (Octagam) in the United States while it investigates blood clots and embolisms linked with the biologic, t...

see more →

Patient Education  4 results see all →